Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants, a severe, rapidly progressive form of chronic kidney disease also known as APOL1-mediated kidney disease (AMKD).

Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)

Moderna

With three pipeline candidates in phase 3 clinical trials, Moderna is set to enter a new phase of growth. CRISPR Therapeutics may soon reach a big milestone -- the launch of its first approved product.

2 Top Biotech Stocks to Buy for the Long Haul

Amazon

Alphabet

The rise of AI and quantum computing could land Alphabet a spot in the Dow. Amazon's e-commerce and cloud-hosting growth could make it an irresistible choice for inclusion in the blue-chip index.

Prediction: These 3 Stocks Will Be in the Dow by 2030

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

Vertex's next launch could open the door to a multibillion-dollar opportunity. The company also has other treatment candidates, not to mention its flagship lineup.

This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a Buy

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Verve Therapeutics

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

DexCom

Healthcare businesses tend to remain resilient even amid economic turmoil. Vertex could soon have another blockbuster on its hands, and its existing portfolio remains strong.

2 Top Stocks to Buy in March and Hold Forever

Shopify

Healthcare and e-commerce aren't going anywhere, even if a full-blown recession hits. Vertex Pharmaceuticals is raking in profits and building out its pipeline for future wins.

2 Explosive Stocks That Could Go Parabolic

CRISPR Therapeutics is a clinical-stage biotech company. The company's pipeline includes two promising wholly owned therapies.

Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a Vertex-developed, immunoprotective device with the potential to treat type 1 diabetes (T1D).

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) 43rd Annual Cowen Healthcare Conference March 7, 2023 2:50 PM ET Company Participants Reshma Kewalramani – President and Chief Executive Officer Charlie Wagner – Chief Financial Officer Conference Call Participants Phil Nadeau – Cowen Phil Nadeau [Call Starts Abruptly] Annual Healthcare Conference. I'm Phil Nadeau, one of Cowen's biotech analysts, and it's my pleasure to do a fireside chat with one of the bellwethers of the industry, Vertex.

Vertex Pharmaceuticals Incorporated (VRTX) 43rd Annual Cowen Healthcare Conference Transcript

The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

Beam Therapeutics could be a huge winner over the long run with its base-editing therapies.

3 Game-Changing Stocks to Buy in March

Digital Realty Trust

These large-cap stocks should grow much larger.

Prediction: These 3 S&P 500 Stocks Will at Least Double in 7 Years

Sirius XM Holdings Inc

The predominantly growth-oriented Nasdaq 100 is home to three amazing deals hiding in plain sight.

3 Nasdaq 100 Stocks to Buy Hand Over Fist in March

Eli Lilly

Madrigal Pharmaceuticals

These top growth stocks sport premium valuations for a very good reason.

3 Incredible Growth Stocks to Buy if the Market Dips

Doximity

Doing this can strengthen your retirement plan.

Here's How Much You Can Make From Investing Your Tax Return Every Year

AbbVie

Gilead Sciences

If cash is king, these three stocks should wear crowns.

3 Stocks to Buy Right Now That Are Cash Cows

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

These three stocks have tremendous growth prospects.

3 Top Stocks to Invest $3,000 in Right Now

Baidu

Intuitive Surgical

Okta

A 33% plunge in the Nasdaq Composite is the perfect excuse for opportunistic investors to pounce on innovation-driven businesses.

Nasdaq Bear Market: 5 Superb Growth Stocks You'll Regret Not Buying on the Dip

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen's 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7

Airbnb

These companies are raking in profits and growing at a speed that outpaces the competition.

Got $1,500? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond

These two stocks are unstoppable leaders.

Chances of a New Bull Market Fading? 2 Great Stocks to Buy Anyway

Pinterest

A pandemic favorite and a healthcare growth stock each have something to add to the long-term investor's portfolio.

News for Vertex Pharmaceuticals Stock (VRTX)